Year Ahead Could Prove Rough For Private Biotech Financing
Financing Forecast: Industry Experts Have Grim Outlook For Private Biotechs
The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.
